CALL - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 08:01:20 2024-06-27 EDT | ||
| 46.36 EUR | +0.78% |
|
| Current month | +22.41% | ||
| 1 month | +23.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 46.36 | +0.78% |
| 24-06-26 | 46 | -0.63% |
| 24-06-25 | 46.29 | +1.29% |
| 24-06-24 | 45.7 | +2.40% |
| 24-06-21 | 44.63 | +0.86% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 08:01 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6NT5 |
| ISIN | DE000VU6NT54 |
| Date issued | 2023-04-27 |
| Strike | 409.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.27 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 46.82 € |
|---|---|
| Lowest since issue | 1.52 € |
| Spread | 0.22 € |
| Spread % | 0.47% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
